preview

Risk-Sharing Schemes : A Case Study

Decent Essays

While risk-sharing schemes have been garnering attention, there are still few new agreements in the United States due to limitations that may require state or plan-specific solutions.
40% of Europe's executed risk-sharing schemes are from France, Germany, Italy, Spain and the UK, combined.
Considering existing pressure on authorities to guarantee early market access of drugs and new challenges caused by new therapeutic mechanisms, managed entry agreements in the EU5 countries will are likely to stay.
Overview

Hello and thank you for sending your inquiry to Wonder about the incidence and prevalence of managed entry agreements or risk-sharing schemes. The short version is that while risk-sharing schemes have garnered considerable attention, …show more content…

However, there are still very few new agreements in the United States.

According to the American Journal of Managed Care or AJMC's review of performance-based risk-sharing or PBRS database, of the 148 RSAs all over the world between the late 1990s and 2013, only 18 of those or 12.2% are United States RSAs, with 11 of the these as public sector coverage with evidence development schemes and the rest are from the private sector. The limited use in the United States is due to the difficulties in implementing and carrying out such schemes. The National Pharmaceutical Council or NPC's study in 2015 showed that performance-based RSAs increased by 2007, gradually declined until 2013 and picked up by 2014. The same study also showed that of the 15 countries, the United States was the third-most in terms of the number of agreements.

There are a number of challenges that have limited MEAs from being implemented in the United States.

1. IT Infrastructure
2. Data Collection and Reporting
3. Budget Predictability — Fragmented multi-payer insurance market and significant patient switching among plans
4. Establishing Strategy / Agreement on Goals
5. Structure & Measurement of Strategy/Goals

There may be implications for federal pricing (Medicaid). Most of these challenges, if not all, require state or plan-specific solutions.

FRANCE, GERMANY, UNITED KINGDOM, SPAIN AND ITALY (EU5)
In Europe, given the complexities

Get Access